{
  "id": 16612774,
  "title": "Next-generation drug reduces endometrial cancer progression and death in trial",
  "url": "https://urgent.news/2026/10/26/next-generation-drug-reduces-endometrial-cancer-progression-and-death",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-26T14:30:04.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-generation-drug-endometrial-cancer-death.html"
  },
  "original_language": "en",
  "account": "A recent international study has shown that a new drug, sacituzumab tirumotecan, can significantly reduce the progression of endometrial cancer and related deaths. This drug, also known as sac-TMT, targets a protein on tumor cells and delivers a targeted dose of a chemical that leads to cancer cell death. Endometrial cancer, which affects the inner lining of the uterus, is becoming more deadly and has limited treatment options, especially when diagnosed late. Currently, there are no standard therapies to prevent or stall its recurrence after initial chemotherapy and immunotherapy.\n\nThe study, led by researchers at NYU Langone Health and its Perlmutter Cancer Center, compared treatment with sac-TMT to standard chemotherapy in women who had already been treated with chemotherapy and immunotherapy for advanced or recurring endometrial cancer. The trial, which included 776 women, found that those who received sac-TMT had a 41% lower risk of their cancer progressing than those who received standard chemotherapy after immunotherapy. Overall, the risk of death within the sac-TMT group was 32% lower than in the standard chemotherapy-treated group. Additionally, more than twice as many women treated with sac-TMT showed a tumor response, such as shrinkage, compared to those treated with standard chemotherapy (35.1% versus 17.3%, respectively).\n\nSide effects in the sac-TMT group were mostly manageable, including low blood counts, mouth inflammation, and dry or itchy eyes. Study co-investigator Michelle Lightfoot, M.D., emphasized the importance of this drug for women worldwide, as endometrial cancer's incidence and mortality are increasing. She highlighted that existing therapies are ineffective, particularly for aggressive subtypes, which are more common in Black patients, who also have a higher risk of dying from the disease.\n\nDr. Bhavana Pothuri, the study's principal investigator and gynecologic oncologist, stated that this Phase III trial's results establish sacituzumab tirumotecan as a new standard treatment for recurrent endometrial cancer. As a result, clinical guidelines for endometrial cancer will need to be reassessed to incorporate sac-TMT. The drug's success also suggests potential for treating other cancers in which Trop-2, the target protein, is overexpressed, such as lung, breast, ovarian, and intestinal tumors.",
  "summary": "A new drug is effective at decreasing the recurrence of, and death from, endometrial cancer, an international study shows. The drug, called sacituzumab tirumotecan (sac-TMT), attaches to a protein on the surface of tumor cells and then delivers a targeted dose of a chemical that leads to cancer cell death.",
  "key_points": [
    "Sacituzumab tirumotecan reduces endometrial cancer progression by 41%",
    "32% lower risk of death in sac-TMT group compared to standard chemo",
    "Drug targets Trop-2 protein on tumor cells, showing tumor response in 35.1%"
  ],
  "editors_take": "Targeting the Trop-2 protein offers a vital lifeline for patients facing aggressive endometrial cancer subtypes that have previously lacked effective standard therapies to prevent recurrence or death.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}